TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01851226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hands-on ERCP training.
Description: The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hands-on ERCP training.
Description: The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hands-on ERCP training.
Description: The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
Study: NCT02798952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B Kinder
Description: Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
Study: NCT01420003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: 3 per study
Study: NCT02176967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT00715442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg by mouth daily for 28 consecutive days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
Study: NCT01420003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsil Biopsy
Description: Optional upon completion of study
Study: NCT00563563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB32
Description: All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ancillary therapy
Description: During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
Study: NCT04394832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive intervention
Description: See the information provided in the experimental arm description.
Study: NCT01306994

Intervention type: OTHER
Intervention: Lactate, Glucose, and Adenosine Triphosphate Blood Levels
Description: Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.

Intervention type: OTHER
Intervention: Lactate, Glucose, and Adenosine Triphosphate Blood Levels
Description: Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.

Intervention type: PROCEDURE
Intervention: Physiological Stress Test
Description: During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
Study: NCT04271280

Intervention type: OTHER
Intervention: Non-interventional
Description: This is a non-interventional study.
Study: NCT03289923

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS + Cognitive therapy
Description: Placebo Transcranial Magnetic Stimulation with cognitive therapy
Study: NCT01306994

Intervention type: PROCEDURE
Intervention: Physiological Stress Test
Description: During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).

Intervention type: OTHER
Intervention: Functional Enquiry Form
Description: Evaluated before clinical examination, it is a checklist of medical problems.

Intervention type: OTHER
Intervention: Functional Enquiry Form
Description: Evaluated before clinical examination, it is a checklist of medical problems.
Study: NCT02176967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound
Study: NCT01306994

Intervention type: OTHER
Intervention: Strength, Joint ROM, Girth and Length Measurements
Description: Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.

Intervention type: OTHER
Intervention: Strength, Joint ROM, Girth and Length Measurements
Description: Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.

Intervention type: OTHER
Intervention: Study Physical Examination
Description: Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).

Intervention type: OTHER
Intervention: Study Physical Examination
Description: Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).

Intervention type: OTHER
Intervention: Observational Gait Analysis
Description: Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.

Intervention type: OTHER
Intervention: Observational Gait Analysis
Description: Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.

Intervention type: OTHER
Intervention: Mental Health Interview
Description: Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.

Intervention type: OTHER
Intervention: Mental Health Interview
Description: Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
Study: NCT03098771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the cell transplantation group
Description: Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the control group
Description: Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
Study: NCT02176967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound
Study: NCT00735358

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate
Description: Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
Study: NCT03495440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center Sessions
Description: Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At-home
Description: Self-study resources paired with regular contact with study personnel.
Study: NCT00735358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Description: Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
Study: NCT04428281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration. In the LTE part, RO7248824 will be administered as IT injection of varying dose levels over a period of 144 weeks, with a minimum of approximately 16 weeks between each dose administration. In the OOE part, participants will receive RO7248824 as an IT injection with the same dosing regime as the LTE part over a period of up to 48 weeks.
Study: NCT02973672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: 4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
Study: NCT01417286

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Hypofractionated accelerated radiation therapy over 11 days
Study: NCT03373786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG012
Description: RG012 in 0.3% sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG012
Description: RG012 in 0.3% sodium chloride
Study: NCT02217735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing Intervention
Description: Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing Intervention
Description: Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
Study: NCT03042949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Description: Blood pressure measurement with a standard plethysmograph

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement with the new device
Description: Blood pressure measurement with the optical sensor, Elfor -1 device.
Study: NCT05115318

Intervention type: DRUG
Intervention: Medical Cannabis
Description: Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
Study: NCT01158950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Drug: Tolcapone 200mg (single dose) administered at study visit

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (200mg) administered at study visit
Study: NCT01469104

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3 day fast
Description: Subjects will fast for 72 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 day CHO-free diet
Description: Subjects will receive a carbohydrate-free diet for 72 hours
Study: NCT02277132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil 25 mg three times daily orally from randomization until delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets three times daily orally from randomization until delivery
Study: NCT03289923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TMS + Cognitive therapy
Description: Active Transcranial Magnetic Stimulation with cognitive therapy.
Study: NCT04399278

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic Test: end-expiratory occlusion (EEO) test
Description: A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~* T0: baseline.~* T1: At the end of the first EEO (15 sec or 30 sec)~* T2: 1 minute after completion of the first EEO. Return to baseline.~* T3: At the end of the second EEO (15 sec or 30 sec)~* T4: 1 minute after completion of the second EEO. Return to baseline.~* T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~* T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic Test: end-expiratory occlusion (EEO) test
Description: A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~* T0: baseline.~* T1: At the end of the first EEO (15 sec or 30 sec)~* T2: 1 minute after completion of the first EEO. Return to baseline.~* T3: At the end of the second EEO (15 sec or 30 sec)~* T4: 1 minute after completion of the second EEO. Return to baseline.~* T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~* T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.).
Study: NCT01933672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 once-daily
Description: Tablets, 300 mg once-daily with breakfast, 14-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 split-dose
Description: tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin once-daily
Description: tablets, 100 mg once-daily with breakfast, 14-days
Study: NCT03993743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD147-CART
Description: Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
Study: NCT00814801

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Description: Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Description: Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
Study: NCT03089983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Participants will receive daily or weekly doses of oral methadone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
Study: NCT03663933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression Only Conditioning
Description: E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Description: E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -11 and -7, cyclophosphamide:3 mg/kg orally daily on days -11 through -4 Busulfan IV, pharmokinetically dosed, on days -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg/kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg/kg on days +5 through +25

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg/kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg/kg on days +5 through +25

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSC
Description: Stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSC
Description: Stem cell transplant
Study: NCT02890069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Study: NCT04430725

Intervention type: PROCEDURE
Intervention: Computed Tomography with Contrast
Description: Undergo contrast-enhanced CT

Intervention type: PROCEDURE
Intervention: Microwave Ablation
Description: Undergo microwave ablation

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies